Hallo! Tracked shipping to Austria with Delivery Duty Paid for just €3.99  

Ship to
Austria
0

My Account

  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional

menu

Select your country

Americas

Europe

Rest of the world

portada Drug Management of Prostate Cancer
Drug Management of Prostate CancerDrug Management of Prostate CancerDrug Management of Prostate CancerDrug Management of Prostate Cancer
Type
Physical Book
Publisher
Author
Language
English
Pages
430
Format
Hardcover
Dimensions
26.2x19.3x3.3 cm
Weight
1.07 kg.
ISBN
1603278311
ISBN13
9781603278317
Categories

Drug Management of Prostate Cancer

Figg, William D. ; Chau, Cindy H. ; Small, Eric J. (Author) · Springer · Hardcover

Drug Management of Prostate Cancer - Figg, William D. ; Chau, Cindy H. ; Small, Eric J.

Cheaper New Book Imported to Austria
Delivery: 30 Oct - 03 Nov Shipping: 15 to 16 business days.
258,73 €
Faster New Book Imported to Austria
Delivery: 28 Oct - 30 Oct Shipping: 13 to 14 business days.
282,71 €
Import costs and 10% VAT included in the price ✅
258,73 €

Choose the list to add your product or create one New List

Go to My Wishlists
Calculate shipping cost

Synopsis "Drug Management of Prostate Cancer"

Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges' report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials.

Customers reviews

More customer reviews
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)

Frequently Asked Questions about the Book

Is the book original?

All books in our catalog are Original.

In what language is the book written?

The book is written in English.

What is the format of this book?

The binding of this edition is Hardcover.

Questions and Answers about the Book

Do you have a question about the book? Login to be able to add your own question.

Opinions about Bookdelivery

More customer reviews